Global Non-Alcoholic Steatohepatitis Diagnostics Market By Offerings (Diagnostic Assays, Others); By Diagnosis (Serum Biomarkers, Liver Biopsy and Liver enzyme testing, Echography, Histological Assessment of Liver Tissue, Physical Examination, Blood Tests, Imaging Tests – Magnetic Resonance Imaging (MRI), Ultrasound, Others, Others); By Patient Type (Adult, Pediatric); By End User (Hospitals and Clinics, Research & Academic Institutes, Diagnostics, Pharma Companies, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of revenue, the global non-alcoholic steatohepatitis diagnostics market is growing at an estimated CAGR of 34% over the forecast period. Non-alcoholic steatohepatitis basically is a liver disease. In this disease, fat builds up in the one’s liver, who hasn’t drink anything or drinks in moderation sometimes. Non-alcoholic steatohepatitis causes the liver to inflame and causes damage to the cells in the liver, and this is likely to turn into liver cirrhosis and also liver failure. People who are suffering from nonalcoholic steatohepatitis are more prone to suffer from liver cancer. This disease is more commonly seen adults of middle age, specifically in those who happen to be overweight or obese or are suffering from chronic diseases like diabetes or high levels of cholesterol and triglycerides. There are numerous factors like sedentary lifestyle and changing work culture that are causing diseases like non-alcoholic steatohepatitis. Meanwhile, diagnosis of utmost importance and first step towards treating any type disease. The non-alcoholic steatohepatitis diagnostics market is aggressively growing courtesy of various factors.
Meanwhile, the coronavirus pandemic proved helpful for the growth of the non-alcoholic steatohepatitis diagnostics market. People with non-fatty liver were more under the risk of being infected from a dreadful virus first found in China. This is why more diagnostic services were sought.
Offerings Outlook
On the basis of offerings, the non-alcoholic steatohepatitis diagnostics market has been divided into diagnostics assays and others. The diagnostic assays segment accounts for majority of revenue generated by this market. Diagnostic assays happen to be laboratory test to determine and measure the amount of a particular substance. It plays crucial role in the process of diagnostic a disease.
Diagnosis Outlook
On the basis of diagnosis, the non-alcoholic steatohepatitis diagnostics market has been categorised into serum biomarkers, liver biopsy and liver enzyme testing, echography, histological assessment of liver tissue, physical examination, blood tests, imaging tests and others. The imaging tests segment was further bifurcated into magnetic resonance imaging (MRI), ultrasound and others. Liver biopsy and liver enzyme testing segment has dominating in terms of market share, as it helps determine the amount of damage done to the liver.
Global Non-Alcoholic Steatohepatitis Diagnostics Market Revenue & Forecast, (US$ Million), 2022 – 2030
Patient Type Outlook
The patient type segment of the non-alcoholic steatohepatitis diagnostics market has been segmented into adult and pediatric. The adult segment mints maximum amount for this market. This ailment is suffered majorly by those suffering from obesity or even are slightly overweight. Also the fact that people suffering chronic diseases like diabetes belong to adult age group. This is exactly why this segment dominates.
End User Outlook
The end user segment of the non-alcoholic steatohepatitis diagnostics market has been bifurcated into hospitals and clinics, research & academic institutes, diagnostics, pharma companies and others. The hospitals and clinics segment accounts for major chunk of money minted by this market. Number of people opting to get themselves treated in hospitals and clinics are more, and this is why these institutes are using latest diagnostics machines.
Region Outlook
On the basis of region, the non-alcoholic steatohepatitis diagnostics market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America accounts for most of the money for this market. Availability of better medical infrastructure along with high awareness about various diseases helps this market grow in the region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global non-alcoholic steatohepatitis diagnostics market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global non-alcoholic steatohepatitis diagnostics market are listed below:
- Galmed
- Genfit
- Intercept
- Other Market Participants
Global Non-Alcoholic Steatohepatitis Diagnostics Market
By Offerings
- Diagnostic Assays
- Others
By Diagnosis
- Serum Biomarkers
- Liver Biopsy and liver enzyme testing
- Echography
- Histological assessment of liver tissue
- Physical Examination
- Blood Tests
- Imaging Tests
- Magnetic resonance imaging (MRI)
- Ultrasound
- Others
- Others
By Patient Type
- Adult Type
- Pediatric
By End-User
- Hospitals and Clinics
- Research & Academic Institutes
- Diagnostics
- Pharma Companies
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Year: 2020
1.2.2.
Base
Year: 2021
1.2.3.
Forecast
Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Non-Alcoholic Steatohepatitis Diagnostics Market
6.
Market
Synopsis:Â Non-Alcoholic Steatohepatitis
Diagnostics Market
7.
Non-Alcoholic
Steatohepatitis Diagnostics Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Non-Alcoholic Steatohepatitis Diagnostics Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Non-Alcoholic Steatohepatitis Diagnostics Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Non-Alcoholic Steatohepatitis Diagnostics Market
8.
Global
Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 –
2030
8.1.
Overview
8.1.1.
Global
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
8.2.
Global
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Offerings
8.2.1.
Diagnostic
Assays
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2020 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2020 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2020 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2020 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2020 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2020 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2.
 Others
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2020 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2020 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2020 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2020 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2020 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2020 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.3.
Key
Segment for Channeling Investments
8.3.1.
By
Offerings
9.
Global
Non-Alcoholic Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 –
2030
9.1.
Overview
9.2.
Global
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
9.2.1.
Serum
Biomarkers
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2020 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2020 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2020 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2020 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2020 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2.
Liver
Biopsy and liver enzyme testing
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2020 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2020 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2020 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2020 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2020 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3.
Echography
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2020 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2020 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2020 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2020 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2020 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4.
Histological
assessment of liver tissue
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2020 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2020 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2020 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2020 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2020 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5.
Physical
Examination
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2020 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2020 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2020 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2020 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2020 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6.
Blood
Tests
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2020 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2020 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2020 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2020 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2020 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.2.7.
Imaging
Tests
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.7.3.
Market
Forecast, 2022 - 2030
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1.
North
America
9.2.7.5.1.1. Market Estimation, 2020 - 2021
9.2.7.5.1.2. Market Forecast, 2022 - 2030
9.2.7.5.2.
Europe
9.2.7.5.2.1. Market Estimation, 2020 - 2021
9.2.7.5.2.2. Market Forecast, 2022 - 2030
9.2.7.5.3.
Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2020 - 2021
9.2.7.5.3.2. Market Forecast, 2022 - 2030
9.2.7.5.4.
Middle
East and Africa
9.2.7.5.4.1. Market Estimation, 2020 - 2021
9.2.7.5.4.2. Market Forecast, 2022 - 2030
9.2.7.5.5.
Latin
America
9.2.7.5.5.1. Market Estimation, 2020 - 2021
9.2.7.5.5.2. Market Forecast, 2022 - 2030
9.2.8.
Magnetic
resonance imaging (MRI) (Definition, Market Estimation and Penetration, 2020 -
2021, Market Estimation (2020 - 2021), Market Forecast (2022 - 2030), Compound
Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia
Pacific, Middle East and Africa, Latin America) and Information on Ultrasound,
Others)
9.2.8.1.
Ultrasound
9.2.8.2.
Others
9.2.9.
Others
9.2.9.1.
Definition
9.2.9.2.
Market
Estimation and Penetration, 2020 - 2021
9.2.9.3.
Market
Forecast, 2022 - 2030
9.2.9.4.
Compound
Annual Growth Rate (CAGR)
9.2.9.5.
Regional
Bifurcation
9.2.9.5.1.
North
America
9.2.9.5.1.1. Market Estimation, 2020 - 2021
9.2.9.5.1.2. Market Forecast, 2022 - 2030
9.2.9.5.2.
Europe
9.2.9.5.2.1. Market Estimation, 2020 - 2021
9.2.9.5.2.2. Market Forecast, 2022 - 2030
9.2.9.5.3.
Asia
Pacific
9.2.9.5.3.1. Market Estimation, 2020 - 2021
9.2.9.5.3.2. Market Forecast, 2022 - 2030
9.2.9.5.4.
Middle
East and Africa
9.2.9.5.4.1. Market Estimation, 2020 - 2021
9.2.9.5.4.2. Market Forecast, 2022 - 2030
9.2.9.5.5.
Latin
America
9.2.9.5.5.1. Market Estimation, 2020 - 2021
9.2.9.5.5.2. Market Forecast, 2022 - 2030
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Diagnosis
10. Global Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type
10.2.1. Adult
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2020 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2020 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2020 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2020 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2020 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2020 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Pediatric
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2020 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2020 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2020 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2020 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2020 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2020 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Patient Type
11. Global Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
11.2.1. Hospitals and Clinics
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2020 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2020 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2020 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2020 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2020 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2020 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Research and Academic Institutes
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2020 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2020 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2020 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2020 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2020 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2020 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Diagnostics
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2020 - 2021
11.2.3.3.
Market
Forecast, 2022 - 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2020 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2020 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2020 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2020 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2020 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.2.4. Pharma Companies
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2020 - 2021
11.2.4.3.
Market
Forecast, 2022 - 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2020 - 2021
11.2.4.5.1.2. Market Forecast, 2022 - 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2020 - 2021
11.2.4.5.2.2. Market Forecast, 2022 - 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2020 - 2021
11.2.4.5.3.2. Market Forecast, 2022 - 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2020 - 2021
11.2.4.5.4.2. Market Forecast, 2022 - 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2020 - 2021
11.2.4.5.5.2. Market Forecast, 2022 - 2030
11.2.5. Others
11.2.5.1.
Definition
11.2.5.2.
Market
Estimation and Penetration, 2020 - 2021
11.2.5.3.
Market
Forecast, 2022 - 2030
11.2.5.4.
Compound
Annual Growth Rate (CAGR)
11.2.5.5.
Regional
Bifurcation
11.2.5.5.1.
North
America
11.2.5.5.1.1. Market Estimation, 2020 - 2021
11.2.5.5.1.2. Market Forecast, 2022 - 2030
11.2.5.5.2.
Europe
11.2.5.5.2.1. Market Estimation, 2020 - 2021
11.2.5.5.2.2. Market Forecast, 2022 - 2030
11.2.5.5.3.
Asia
Pacific
11.2.5.5.3.1. Market Estimation, 2020 - 2021
11.2.5.5.3.2. Market Forecast, 2022 - 2030
11.2.5.5.4.
Middle
East and Africa
11.2.5.5.4.1. Market Estimation, 2020 - 2021
11.2.5.5.4.2. Market Forecast, 2022 - 2030
11.2.5.5.5.
Latin
America
11.2.5.5.5.1. Market Estimation, 2020 - 2021
11.2.5.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End-User
12. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn)
12.2. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.2.1. Diagnostic Assays
12.2.2. Â Others
12.3. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.3.1. Serum Biomarkers
12.3.2. Liver Biopsy and liver enzyme testing
12.3.3. Echography
12.3.4. Histological assessment of liver tissue
12.3.5. Physical Examination
12.3.6. Blood Tests
12.3.7. Imaging Tests
12.3.8. Magnetic resonance imaging (MRI)
12.3.8.1.
Ultrasound
12.3.8.2.
Others
12.3.9. Others
12.4. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type
12.4.1. Adult
12.4.2. Pediatric
12.5. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1. Hospitals and Clinics
12.5.2. Research and Academic Institutes
12.5.3. Diagnostics
12.5.4. Pharma Companies
12.5.5. Others
12.6. North America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
12.6.1.1.1.
Diagnostic
Assays
12.6.1.1.2.
 Others
12.6.1.2.
U.S
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
12.6.1.2.1.
Serum
Biomarkers
12.6.1.2.2.
Liver
Biopsy and liver enzyme testing
12.6.1.2.3.
Echography
12.6.1.2.4.
Histological
assessment of liver tissue
12.6.1.2.5.
Physical
Examination
12.6.1.2.6.
Blood
Tests
12.6.1.2.7.
Imaging
Tests
12.6.1.2.8.
Magnetic
resonance imaging (MRI)
12.6.1.2.8.1. Ultrasound
12.6.1.2.8.2. Others
12.6.1.2.9.
Others
12.6.1.3.
U.S
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
12.6.1.3.1.
Adult
12.6.1.3.2.
Pediatric
12.6.1.4.
U.S
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
12.6.1.4.1.
Hospitals
and Clinics
12.6.1.4.2.
Research
and Academic Institutes
12.6.1.4.3.
Diagnostics
12.6.1.4.4.
Pharma
Companies
12.6.1.4.5.
Others
12.6.2. Canada
12.6.2.1.
Canada
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
12.6.2.1.1.
Diagnostic
Assays
12.6.2.1.2.
 Others
12.6.2.2.
Canada
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.6.2.2.1.
Serum
Biomarkers
12.6.2.2.2.
Liver
Biopsy and liver enzyme testing
12.6.2.2.3.
Echography
12.6.2.2.4.
Histological
assessment of liver tissue
12.6.2.2.5.
Physical
Examination
12.6.2.2.6.
Blood
Tests
12.6.2.2.7.
Imaging
Tests
12.6.2.2.8.
Magnetic
resonance imaging (MRI)
12.6.2.2.8.1. Ultrasound
12.6.2.2.8.2. Others
12.6.2.2.9.
Others
12.6.2.3.
Canada
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
12.6.2.3.1.
Adult
12.6.2.3.2.
Pediatric
12.6.2.4.
Canada
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
12.6.2.4.1.
Hospitals
and Clinics
12.6.2.4.2.
Research
and Academic Institutes
12.6.2.4.3.
Diagnostics
12.6.2.4.4.
Pharma
Companies
12.6.2.4.5.
Others
12.6.3. Mexico
12.6.3.1.
Mexico
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
12.6.3.1.1.
Diagnostic
Assays
12.6.3.1.2.
 Others
12.6.3.2.
Mexico
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.6.3.2.1.
Serum
Biomarkers
12.6.3.2.2.
Liver
Biopsy and liver enzyme testing
12.6.3.2.3.
Echography
12.6.3.2.4.
Histological
assessment of liver tissue
12.6.3.2.5.
Physical
Examination
12.6.3.2.6.
Blood
Tests
12.6.3.2.7.
Imaging
Tests
12.6.3.2.8.
Magnetic
resonance imaging (MRI)
12.6.3.2.8.1. Ultrasound
12.6.3.2.8.2. Others
12.6.3.2.9.
Others
12.6.3.3.
Mexico
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
12.6.3.3.1.
Adult
12.6.3.3.2.
Pediatric
12.6.3.4.
Mexico
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
12.6.3.4.1.
Hospitals
and Clinics
12.6.3.4.2.
Research
and Academic Institutes
12.6.3.4.3.
Diagnostics
12.6.3.4.4.
Pharma
Companies
12.6.3.4.5.
Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Offerings
12.6.4.1.1.
Diagnostic
Assays
12.6.4.1.2.
 Others
12.6.4.2.
Rest of
North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
12.6.4.2.1.
Serum
Biomarkers
12.6.4.2.2.
Liver
Biopsy and liver enzyme testing
12.6.4.2.3.
Echography
12.6.4.2.4.
Histological
assessment of liver tissue
12.6.4.2.5.
Physical
Examination
12.6.4.2.6.
Blood
Tests
12.6.4.2.7.
Imaging
Tests
12.6.4.2.8.
Magnetic
resonance imaging (MRI)
12.6.4.2.8.1. Ultrasound
12.6.4.2.8.2. Others
12.6.4.2.9.
Others
12.6.4.3.
Rest of
North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Patient Type
12.6.4.3.1.
Adult
12.6.4.3.2.
Pediatric
12.6.4.4.
Rest of
North America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By End-User
12.6.4.4.1.
Hospitals
and Clinics
12.6.4.4.2.
Research
and Academic Institutes
12.6.4.4.3.
Diagnostics
12.6.4.4.4.
Pharma
Companies
12.6.4.4.5.
Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Offerings
12.7.3. By Diagnosis
12.7.4. By Patient Type
12.7.5. By End-User
13. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn)
13.2. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.2.1. Diagnostic Assays
13.2.2. Â Others
13.3. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.3.1. Serum Biomarkers
13.3.2. Liver Biopsy and liver enzyme testing
13.3.3. Echography
13.3.4. Histological assessment of liver tissue
13.3.5. Physical Examination
13.3.6. Blood Tests
13.3.7. Imaging Tests
13.3.8. Magnetic resonance imaging (MRI)
13.3.8.1.
Ultrasound
13.3.8.2.
Others
13.3.9. Others
13.4. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type
13.4.1. Adult
13.4.2. Pediatric
13.5. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1. Hospitals and Clinics
13.5.2. Research and Academic Institutes
13.5.3. Diagnostics
13.5.4. Pharma Companies
13.5.5. Others
13.6. Europe Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.1.1.1.
Diagnostic
Assays
13.6.1.1.2.
 Others
13.6.1.2.
France
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.1.2.1.
Serum
Biomarkers
13.6.1.2.2.
Liver
Biopsy and liver enzyme testing
13.6.1.2.3.
Echography
13.6.1.2.4.
Histological
assessment of liver tissue
13.6.1.2.5.
Physical
Examination
13.6.1.2.6.
Blood
Tests
13.6.1.2.7.
Imaging
Tests
13.6.1.2.8.
Magnetic
resonance imaging (MRI)
13.6.1.2.8.1. Ultrasound
13.6.1.2.8.2. Others
13.6.1.2.9.
Others
13.6.1.3.
France
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.1.3.1.
Adult
13.6.1.3.2.
Pediatric
13.6.1.4.
France
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.1.4.1.
Hospitals
and Clinics
13.6.1.4.2.
Research
and Academic Institutes
13.6.1.4.3.
Diagnostics
13.6.1.4.4.
Pharma
Companies
13.6.1.4.5.
Others
13.6.2. The UK
13.6.2.1.
The UK
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.2.1.1.
Diagnostic
Assays
13.6.2.1.2.
 Others
13.6.2.2.
The UK
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.2.2.1.
Serum
Biomarkers
13.6.2.2.2.
Liver
Biopsy and liver enzyme testing
13.6.2.2.3.
Echography
13.6.2.2.4.
Histological
assessment of liver tissue
13.6.2.2.5.
Physical
Examination
13.6.2.2.6.
Blood
Tests
13.6.2.2.7.
Imaging
Tests
13.6.2.2.8.
Magnetic
resonance imaging (MRI)
13.6.2.2.8.1. Ultrasound
13.6.2.2.8.2. Others
13.6.2.2.9.
Others
13.6.2.3.
The UK
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.2.3.1.
Adult
13.6.2.3.2.
Pediatric
13.6.2.4.
The UK
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.2.4.1.
Hospitals
and Clinics
13.6.2.4.2.
Research
and Academic Institutes
13.6.2.4.3.
Diagnostics
13.6.2.4.4.
Pharma
Companies
13.6.2.4.5.
Others
13.6.3. Spain
13.6.3.1.
Spain
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.3.1.1.
Diagnostic
Assays
13.6.3.1.2.
 Others
13.6.3.2.
Spain
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.3.2.1.
Serum
Biomarkers
13.6.3.2.2.
Liver
Biopsy and liver enzyme testing
13.6.3.2.3.
Echography
13.6.3.2.4.
Histological
assessment of liver tissue
13.6.3.2.5.
Physical
Examination
13.6.3.2.6.
Blood
Tests
13.6.3.2.7.
Imaging
Tests
13.6.3.2.8.
Magnetic
resonance imaging (MRI)
13.6.3.2.8.1. Ultrasound
13.6.3.2.8.2. Others
13.6.3.2.9.
Others
13.6.3.3.
Spain
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.3.3.1.
Adult
13.6.3.3.2.
Pediatric
13.6.3.4.
Spain
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.3.4.1.
Hospitals
and Clinics
13.6.3.4.2.
Research
and Academic Institutes
13.6.3.4.3.
Diagnostics
13.6.3.4.4.
Pharma
Companies
13.6.3.4.5.
Others
13.6.4. Germany
13.6.4.1.
Germany Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.4.1.1.
Diagnostic
Assays
13.6.4.1.2.
 Others
13.6.4.2.
Germany
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.4.2.1.
Serum
Biomarkers
13.6.4.2.2.
Liver
Biopsy and liver enzyme testing
13.6.4.2.3.
Echography
13.6.4.2.4.
Histological
assessment of liver tissue
13.6.4.2.5.
Physical
Examination
13.6.4.2.6.
Blood
Tests
13.6.4.2.7.
Imaging
Tests
13.6.4.2.8.
Magnetic
resonance imaging (MRI)
13.6.4.2.8.1. Ultrasound
13.6.4.2.8.2. Others
13.6.4.2.9.
Others
13.6.4.3.
Germany
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Patient Type
13.6.4.3.1.
Adult
13.6.4.3.2.
Pediatric
13.6.4.4.
Germany
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.4.4.1.
Hospitals
and Clinics
13.6.4.4.2.
Research
and Academic Institutes
13.6.4.4.3.
Diagnostics
13.6.4.4.4.
Pharma
Companies
13.6.4.4.5.
Others
13.6.5. Italy
13.6.5.1.
Italy
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.5.1.1.
Diagnostic
Assays
13.6.5.1.2.
 Others
13.6.5.2.
Italy
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.5.2.1.
Serum
Biomarkers
13.6.5.2.2.
Liver
Biopsy and liver enzyme testing
13.6.5.2.3.
Echography
13.6.5.2.4.
Histological
assessment of liver tissue
13.6.5.2.5.
Physical
Examination
13.6.5.2.6.
Blood
Tests
13.6.5.2.7.
Imaging
Tests
13.6.5.2.8.
Magnetic
resonance imaging (MRI)
13.6.5.2.8.1. Ultrasound
13.6.5.2.8.2. Others
13.6.5.2.9.
Others
13.6.5.3.
Italy
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Patient Type
13.6.5.3.1.
Adult
13.6.5.3.2.
Pediatric
13.6.5.4.
Italy
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.5.4.1.
Hospitals
and Clinics
13.6.5.4.2.
Research
and Academic Institutes
13.6.5.4.3.
Diagnostics
13.6.5.4.4.
Pharma
Companies
13.6.5.4.5.
Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic Countries
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.6.1.1.
Diagnostic
Assays
13.6.6.1.2.
 Others
13.6.6.2.
Nordic
Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.6.2.1.
Serum Biomarkers
13.6.6.2.2.
Liver
Biopsy and liver enzyme testing
13.6.6.2.3.
Echography
13.6.6.2.4.
Histological
assessment of liver tissue
13.6.6.2.5.
Physical
Examination
13.6.6.2.6.
Blood
Tests
13.6.6.2.7.
Imaging
Tests
13.6.6.2.8.
Magnetic
resonance imaging (MRI)
13.6.6.2.8.1. Ultrasound
13.6.6.2.8.2. Others
13.6.6.2.9.
Others
13.6.6.3.
Nordic
Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.6.3.1.
Adult
13.6.6.3.2.
Pediatric
13.6.6.4.
Nordic
Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.6.4.1.
Hospitals
and Clinics
13.6.6.4.2.
Research
and Academic Institutes
13.6.6.4.3.
Diagnostics
13.6.6.4.4.
Pharma
Companies
13.6.6.4.5.
Others
13.6.6.5.
Nordic
Countries Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.7.1.1.
Diagnostic
Assays
13.6.7.1.2.
 Others
13.6.7.2.
Benelux
Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.7.2.1.
Serum
Biomarkers
13.6.7.2.2.
Liver
Biopsy and liver enzyme testing
13.6.7.2.3.
Echography
13.6.7.2.4.
Histological
assessment of liver tissue
13.6.7.2.5.
Physical
Examination
13.6.7.2.6.
Blood
Tests
13.6.7.2.7.
Imaging
Tests
13.6.7.2.8.
Magnetic
resonance imaging (MRI)
13.6.7.2.8.1. Ultrasound
13.6.7.2.8.2. Others
13.6.7.2.9.
Others
13.6.7.3.
Benelux
Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.7.3.1.
Adult
13.6.7.3.2.
Pediatric
13.6.7.4.
Benelux
Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.7.4.1.
Hospitals
and Clinics
13.6.7.4.2.
Research
and Academic Institutes
13.6.7.4.3.
Diagnostics
13.6.7.4.4.
Pharma
Companies
13.6.7.4.5.
Others
13.6.7.5.
Benelux
Union Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
13.6.8.1.1.
Diagnostic
Assays
13.6.8.1.2.
 Others
13.6.8.2.
Rest of
Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.6.8.2.1.
Serum
Biomarkers
13.6.8.2.2.
Liver
Biopsy and liver enzyme testing
13.6.8.2.3.
Echography
13.6.8.2.4.
Histological
assessment of liver tissue
13.6.8.2.5.
Physical
Examination
13.6.8.2.6.
Blood
Tests
13.6.8.2.7.
Imaging
Tests
13.6.8.2.8.
Magnetic
resonance imaging (MRI)
13.6.8.2.8.1. Ultrasound
13.6.8.2.8.2. Others
13.6.8.2.9.
Others
13.6.8.3.
Rest of
Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
13.6.8.3.1.
Adult
13.6.8.3.2.
Pediatric
13.6.8.4.
Rest of
Europe Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
13.6.8.4.1.
Hospitals
and Clinics
13.6.8.4.2.
Research
and Academic Institutes
13.6.8.4.3.
Diagnostics
13.6.8.4.4.
Pharma
Companies
13.6.8.4.5.
Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Offerings
13.7.3. By Diagnosis
13.7.4. By Patient Type
13.7.5. By End-User
14. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn)
14.2. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.2.1. Diagnostic Assays
14.2.2. Â Others
14.3. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.3.1. Serum Biomarkers
14.3.2. Liver Biopsy and liver enzyme testing
14.3.3. Echography
14.3.4. Histological assessment of liver tissue
14.3.5. Physical Examination
14.3.6. Blood Tests
14.3.7. Imaging Tests
14.3.8. Magnetic resonance imaging (MRI)
14.3.8.1.
Ultrasound
14.3.8.2.
Others
14.3.9. Others
14.4. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type
14.4.1. Adult
14.4.2. Pediatric
14.5. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.1. Hospitals and Clinics
14.5.2. Research and Academic Institutes
14.5.3. Diagnostics
14.5.4. Pharma Companies
14.5.5. Others
14.6. Asia Pacific Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.1.1.1.
Diagnostic
Assays
14.6.1.1.2.
 Others
14.6.1.2.
China
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.6.1.2.1.
Serum
Biomarkers
14.6.1.2.2.
Liver
Biopsy and liver enzyme testing
14.6.1.2.3.
Echography
14.6.1.2.4.
Histological
assessment of liver tissue
14.6.1.2.5.
Physical
Examination
14.6.1.2.6.
Blood
Tests
14.6.1.2.7.
Imaging
Tests
14.6.1.2.8.
Magnetic
resonance imaging (MRI)
14.6.1.2.8.1. Ultrasound
14.6.1.2.8.2. Others
14.6.1.2.9.
Others
14.6.1.3.
China
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.1.3.1.
Adult
14.6.1.3.2.
Pediatric
14.6.1.4.
China
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.1.4.1.
Hospitals
and Clinics
14.6.1.4.2.
Research
and Academic Institutes
14.6.1.4.3.
Diagnostics
14.6.1.4.4.
Pharma
Companies
14.6.1.4.5.
Others
14.6.2. Japan
14.6.2.1.
Japan
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.2.1.1.
Diagnostic
Assays
14.6.2.1.2.
 Others
14.6.2.2.
Japan
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.2.2.1.
Serum
Biomarkers
14.6.2.2.2.
Liver
Biopsy and liver enzyme testing
14.6.2.2.3.
Echography
14.6.2.2.4.
Histological
assessment of liver tissue
14.6.2.2.5.
Physical
Examination
14.6.2.2.6.
Blood
Tests
14.6.2.2.7.
Imaging
Tests
14.6.2.2.8.
Magnetic
resonance imaging (MRI)
14.6.2.2.8.1. Ultrasound
14.6.2.2.8.2. Others
14.6.2.2.9.
Others
14.6.2.3.
Japan
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.2.3.1.
Adult
14.6.2.3.2.
Pediatric
14.6.2.4.
Japan
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.2.4.1.
Hospitals
and Clinics
14.6.2.4.2.
Research
and Academic Institutes
14.6.2.4.3.
Diagnostics
14.6.2.4.4.
Pharma
Companies
14.6.2.4.5.
Others
14.6.3. India
14.6.3.1.
India
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.3.1.1.
Diagnostic
Assays
14.6.3.1.2.
 Others
14.6.3.2.
India
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.3.2.1.
Serum
Biomarkers
14.6.3.2.2.
Liver
Biopsy and liver enzyme testing
14.6.3.2.3.
Echography
14.6.3.2.4.
Histological
assessment of liver tissue
14.6.3.2.5.
Physical
Examination
14.6.3.2.6.
Blood
Tests
14.6.3.2.7.
Imaging
Tests
14.6.3.2.8.
Magnetic
resonance imaging (MRI)
14.6.3.2.8.1. Ultrasound
14.6.3.2.8.2. Others
14.6.3.2.9.
Others
14.6.3.3.
India
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.3.3.1.
Adult
14.6.3.3.2.
Pediatric
14.6.3.4.
India
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.3.4.1.
Hospitals
and Clinics
14.6.3.4.2.
Research
and Academic Institutes
14.6.3.4.3.
Diagnostics
14.6.3.4.4.
Pharma Companies
14.6.3.4.5.
Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.4.1.1.
Diagnostic
Assays
14.6.4.1.2.
 Others
14.6.4.2.
New
Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.4.2.1.
Serum
Biomarkers
14.6.4.2.2.
Liver
Biopsy and liver enzyme testing
14.6.4.2.3.
Echography
14.6.4.2.4.
Histological
assessment of liver tissue
14.6.4.2.5.
Physical
Examination
14.6.4.2.6.
Blood
Tests
14.6.4.2.7.
Imaging
Tests
14.6.4.2.8.
Magnetic
resonance imaging (MRI)
14.6.4.2.8.1. Ultrasound
14.6.4.2.8.2. Others
14.6.4.2.9.
Others
14.6.4.3.
New
Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.4.3.1.
Adult
14.6.4.3.2.
Pediatric
14.6.4.4.
New
Zealand Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.4.4.1.
Hospitals
and Clinics
14.6.4.4.2.
Research
and Academic Institutes
14.6.4.4.3.
Diagnostics
14.6.4.4.4.
Pharma
Companies
14.6.4.4.5.
Others
14.6.5. Australia
14.6.5.1.
Australia
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.5.1.1.
Diagnostic
Assays
14.6.5.1.2.
 Others
14.6.5.2.
Australia
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.6.5.2.1.
Serum
Biomarkers
14.6.5.2.2.
Liver
Biopsy and liver enzyme testing
14.6.5.2.3.
Echography
14.6.5.2.4.
Histological
assessment of liver tissue
14.6.5.2.5.
Physical
Examination
14.6.5.2.6.
Blood
Tests
14.6.5.2.7.
Imaging
Tests
14.6.5.2.8.
Magnetic
resonance imaging (MRI)
14.6.5.2.8.1. Ultrasound
14.6.5.2.8.2. Others
14.6.5.2.9.
Others
14.6.5.3.
Australia
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.5.3.1.
Adult
14.6.5.3.2.
Pediatric
14.6.5.4.
Australia
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.5.4.1.
Hospitals
and Clinics
14.6.5.4.2.
Research
and Academic Institutes
14.6.5.4.3.
Diagnostics
14.6.5.4.4.
Pharma
Companies
14.6.5.4.5.
Others
14.6.6. South Korea
14.6.6.1.
South
Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.6.1.1.
Diagnostic
Assays
14.6.6.1.2.
 Others
14.6.6.2.
South
Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.6.2.1.
Serum
Biomarkers
14.6.6.2.2.
Liver
Biopsy and liver enzyme testing
14.6.6.2.3.
Echography
14.6.6.2.4.
Histological
assessment of liver tissue
14.6.6.2.5.
Physical
Examination
14.6.6.2.6.
Blood
Tests
14.6.6.2.7.
Imaging
Tests
14.6.6.2.8.
Magnetic
resonance imaging (MRI)
14.6.6.2.8.1. Ultrasound
14.6.6.2.8.2. Others
14.6.6.2.9.
Others
14.6.6.3.
South
Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.6.3.1.
Adult
14.6.6.3.2.
Pediatric
14.6.6.4.
South
Korea Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.6.4.1.
Hospitals
and Clinics
14.6.6.4.2.
Research
and Academic Institutes
14.6.6.4.3.
Diagnostics
14.6.6.4.4.
Pharma
Companies
14.6.6.4.5.
Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
14.6.7.1.1.
Diagnostic
Assays
14.6.7.1.2.
 Others
14.6.7.2.
Southeast
Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.7.2.1.
Serum
Biomarkers
14.6.7.2.2.
Liver
Biopsy and liver enzyme testing
14.6.7.2.3.
Echography
14.6.7.2.4.
Histological
assessment of liver tissue
14.6.7.2.5.
Physical
Examination
14.6.7.2.6.
Blood
Tests
14.6.7.2.7.
Imaging
Tests
14.6.7.2.8.
Magnetic
resonance imaging (MRI)
14.6.7.2.8.1. Ultrasound
14.6.7.2.8.2. Others
14.6.7.2.9.
Others
14.6.7.3.
Southeast
Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.7.3.1.
Adult
14.6.7.3.2.
Pediatric
14.6.7.4.
Southeast
Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.7.4.1.
Hospitals
and Clinics
14.6.7.4.2.
Research
and Academic Institutes
14.6.7.4.3.
Diagnostics
14.6.7.4.4.
Pharma
Companies
14.6.7.4.5.
Others
14.6.7.5.
Southeast
Asia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Offerings
14.6.8.1.1.
Diagnostic
Assays
14.6.8.1.2.
 Others
14.6.8.2.
Rest of
Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
14.6.8.2.1.
Serum
Biomarkers
14.6.8.2.2.
Liver
Biopsy and liver enzyme testing
14.6.8.2.3.
Echography
14.6.8.2.4.
Histological
assessment of liver tissue
14.6.8.2.5.
Physical
Examination
14.6.8.2.6.
Blood
Tests
14.6.8.2.7.
Imaging
Tests
14.6.8.2.8.
Magnetic
resonance imaging (MRI)
14.6.8.2.8.1. Ultrasound
14.6.8.2.8.2. Others
14.6.8.2.9.
Others
14.6.8.3.
Rest of
Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Patient Type
14.6.8.3.1.
Adult
14.6.8.3.2.
Pediatric
14.6.8.4.
Rest of
Asia Pacific Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By End-User
14.6.8.4.1.
Hospitals
and Clinics
14.6.8.4.2.
Research
and Academic Institutes
14.6.8.4.3.
Diagnostics
14.6.8.4.4.
Pharma
Companies
14.6.8.4.5.
Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Offerings
14.7.3. By Diagnosis
14.7.4. By Patient Type
14.7.5. By End-User
15. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn)
15.2. Middle East and Africa Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.2.1. Diagnostic Assays
15.2.2. Â Others
15.3. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.3.1. Serum Biomarkers
15.3.2. Liver Biopsy and liver enzyme testing
15.3.3. Echography
15.3.4. Histological assessment of liver tissue
15.3.5. Physical Examination
15.3.6. Blood Tests
15.3.7. Imaging Tests
15.3.8. Magnetic resonance imaging (MRI)
15.3.8.1.
Ultrasound
15.3.8.2.
Others
15.3.9. Others
15.4. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient
Type
15.4.1. Adult
15.4.2. Pediatric
15.5. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1. Hospitals and Clinics
15.5.2. Research and Academic Institutes
15.5.3. Diagnostics
15.5.4. Pharma Companies
15.5.5. Others
15.6. Middle East and Africa Non-Alcoholic
Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.6.1.1.1.
Diagnostic
Assays
15.6.1.1.2.
 Others
15.6.1.2.
Saudi
Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.1.2.1.
Serum
Biomarkers
15.6.1.2.2.
Liver
Biopsy and liver enzyme testing
15.6.1.2.3.
Echography
15.6.1.2.4.
Histological
assessment of liver tissue
15.6.1.2.5.
Physical
Examination
15.6.1.2.6.
Blood
Tests
15.6.1.2.7.
Imaging
Tests
15.6.1.2.8.
Magnetic
resonance imaging (MRI)
15.6.1.2.8.1. Ultrasound
15.6.1.2.8.2. Others
15.6.1.2.9.
Others
15.6.1.3.
Saudi
Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.1.3.1.
Adult
15.6.1.3.2.
Pediatric
15.6.1.4.
Saudi
Arabia Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.1.4.1.
Hospitals
and Clinics
15.6.1.4.2.
Research
and Academic Institutes
15.6.1.4.3.
Diagnostics
15.6.1.4.4.
Pharma
Companies
15.6.1.4.5.
Others
15.6.2. UAE
15.6.2.1.
UAE
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.6.2.1.1.
Diagnostic
Assays
15.6.2.1.2.
 Others
15.6.2.2.
UAE
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.2.2.1.
Serum
Biomarkers
15.6.2.2.2.
Liver
Biopsy and liver enzyme testing
15.6.2.2.3.
Echography
15.6.2.2.4.
Histological
assessment of liver tissue
15.6.2.2.5.
Physical
Examination
15.6.2.2.6.
Blood
Tests
15.6.2.2.7.
Imaging
Tests
15.6.2.2.8.
Magnetic
resonance imaging (MRI)
15.6.2.2.8.1. Ultrasound
15.6.2.2.8.2. Others
15.6.2.2.9.
Others
15.6.2.3.
UAE
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.2.3.1.
Adult
15.6.2.3.2.
Pediatric
15.6.2.4.
UAE
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.2.4.1.
Hospitals
and Clinics
15.6.2.4.2.
Research
and Academic Institutes
15.6.2.4.3.
Diagnostics
15.6.2.4.4.
Pharma
Companies
15.6.2.4.5.
Others
15.6.3. Egypt
15.6.3.1.
Egypt
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.6.3.1.1.
Diagnostic
Assays
15.6.3.1.2.
 Others
15.6.3.2.
Egypt
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.3.2.1.
Serum
Biomarkers
15.6.3.2.2.
Liver
Biopsy and liver enzyme testing
15.6.3.2.3.
Echography
15.6.3.2.4.
Histological
assessment of liver tissue
15.6.3.2.5.
Physical
Examination
15.6.3.2.6.
Blood
Tests
15.6.3.2.7.
Imaging Tests
15.6.3.2.8.
Magnetic
resonance imaging (MRI)
15.6.3.2.8.1. Ultrasound
15.6.3.2.8.2. Others
15.6.3.2.9.
Others
15.6.3.3.
Egypt
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.3.3.1.
Adult
15.6.3.3.2.
Pediatric
15.6.3.4.
Egypt
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.3.4.1.
Hospitals
and Clinics
15.6.3.4.2.
Research
and Academic Institutes
15.6.3.4.3.
Diagnostics
15.6.3.4.4.
Pharma
Companies
15.6.3.4.5.
Others
15.6.4. Kuwait
15.6.4.1.
Kuwait
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.6.4.1.1.
Diagnostic
Assays
15.6.4.1.2.
 Others
15.6.4.2.
Kuwait
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.4.2.1.
Serum
Biomarkers
15.6.4.2.2.
Liver
Biopsy and liver enzyme testing
15.6.4.2.3.
Echography
15.6.4.2.4.
Histological
assessment of liver tissue
15.6.4.2.5.
Physical
Examination
15.6.4.2.6.
Blood
Tests
15.6.4.2.7.
Imaging
Tests
15.6.4.2.8.
Magnetic
resonance imaging (MRI)
15.6.4.2.8.1. Ultrasound
15.6.4.2.8.2. Others
15.6.4.2.9.
Others
15.6.4.3.
Kuwait
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.4.3.1.
Adult
15.6.4.3.2.
Pediatric
15.6.4.4.
Kuwait
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End-User
15.6.4.4.1.
Hospitals
and Clinics
15.6.4.4.2.
Research
and Academic Institutes
15.6.4.4.3.
Diagnostics
15.6.4.4.4.
Pharma
Companies
15.6.4.4.5.
Others
15.6.5. South Africa
15.6.5.1.
South
Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
15.6.5.1.1.
Diagnostic
Assays
15.6.5.1.2.
 Others
15.6.5.2.
South
Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.5.2.1.
Serum
Biomarkers
15.6.5.2.2.
Liver
Biopsy and liver enzyme testing
15.6.5.2.3.
Echography
15.6.5.2.4.
Histological
assessment of liver tissue
15.6.5.2.5.
Physical
Examination
15.6.5.2.6.
Blood
Tests
15.6.5.2.7.
Imaging
Tests
15.6.5.2.8.
Magnetic
resonance imaging (MRI)
15.6.5.2.8.1. Ultrasound
15.6.5.2.8.2. Others
15.6.5.2.9.
Others
15.6.5.3.
South
Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.5.3.1.
Adult
15.6.5.3.2.
Pediatric
15.6.5.4.
South
Africa Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.5.4.1.
Hospitals
and Clinics
15.6.5.4.2.
Research
and Academic Institutes
15.6.5.4.3.
Diagnostics
15.6.5.4.4.
Pharma
Companies
15.6.5.4.5.
Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Offerings
15.6.6.1.1.
Diagnostic
Assays
15.6.6.1.2.
 Others
15.6.6.2.
Rest of
Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
15.6.6.2.1.
Serum
Biomarkers
15.6.6.2.2.
Liver
Biopsy and liver enzyme testing
15.6.6.2.3.
Echography
15.6.6.2.4.
Histological
assessment of liver tissue
15.6.6.2.5.
Physical
Examination
15.6.6.2.6.
Blood
Tests
15.6.6.2.7.
Imaging
Tests
15.6.6.2.8.
Magnetic
resonance imaging (MRI)
15.6.6.2.8.1. Ultrasound
15.6.6.2.8.2. Others
15.6.6.2.9.
Others
15.6.6.3.
Rest of
Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Patient Type
15.6.6.3.1.
Adult
15.6.6.3.2.
Pediatric
15.6.6.4.
Rest of
Middle East & Africa Non-Alcoholic Steatohepatitis Diagnostics Market
Revenue (US$ Mn) and Forecasts, By End-User
15.6.6.4.1.
Hospitals
and Clinics
15.6.6.4.2.
Research
and Academic Institutes
15.6.6.4.3.
Diagnostics
15.6.6.4.4.
Pharma
Companies
15.6.6.4.5.
Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Offerings
15.7.3. By Diagnosis
15.7.4. By Patient Type
15.7.5. By End-User
16. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn)
16.2. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
16.2.1. Diagnostic Assays
16.2.2. Â Others
16.3. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Diagnosis
16.3.1. Serum Biomarkers
16.3.2. Liver Biopsy and liver enzyme testing
16.3.3. Echography
16.3.4. Histological assessment of liver tissue
16.3.5. Physical Examination
16.3.6. Blood Tests
16.3.7. Imaging Tests
16.3.8. Magnetic resonance imaging (MRI)
16.3.8.1.
Ultrasound
16.3.8.2.
Others
16.3.9. Others
16.4. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Patient Type
16.4.1. Adult
16.4.2. Pediatric
16.5. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-User
16.5.1. Hospitals and Clinics
16.5.2. Research and Academic Institutes
16.5.3. Diagnostics
16.5.4. Pharma Companies
16.5.5. Others
16.6. Latin America Non-Alcoholic Steatohepatitis
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
16.6.1.1.1.
Diagnostic
Assays
16.6.1.1.2.
 Others
16.6.1.2.
Brazil
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.6.1.2.1.
Serum
Biomarkers
16.6.1.2.2.
Liver
Biopsy and liver enzyme testing
16.6.1.2.3.
Echography
16.6.1.2.4.
Histological
assessment of liver tissue
16.6.1.2.5.
Physical
Examination
16.6.1.2.6.
Blood
Tests
16.6.1.2.7.
Imaging
Tests
16.6.1.2.8.
Magnetic
resonance imaging (MRI)
16.6.1.2.8.1. Ultrasound
16.6.1.2.8.2. Others
16.6.1.2.9.
Others
16.6.1.3.
Brazil
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
16.6.1.3.1.
Adult
16.6.1.3.2.
Pediatric
16.6.1.4.
Brazil
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
16.6.1.4.1.
Hospitals
and Clinics
16.6.1.4.2.
Research
and Academic Institutes
16.6.1.4.3.
Diagnostics
16.6.1.4.4.
Pharma
Companies
16.6.1.4.5.
Others
16.6.2. Argentina
16.6.2.1.
Argentina
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offerings
16.6.2.1.1.
Diagnostic
Assays
16.6.2.1.2.
 Others
16.6.2.2.
Argentina
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.6.2.2.1.
Serum
Biomarkers
16.6.2.2.2.
Liver
Biopsy and liver enzyme testing
16.6.2.2.3.
Echography
16.6.2.2.4.
Histological
assessment of liver tissue
16.6.2.2.5.
Physical
Examination
16.6.2.2.6.
Blood
Tests
16.6.2.2.7.
Imaging
Tests
16.6.2.2.8.
Magnetic
resonance imaging (MRI)
16.6.2.2.8.1. Ultrasound
16.6.2.2.8.2. Others
16.6.2.2.9.
Others
16.6.2.3.
Argentina
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Patient Type
16.6.2.3.1.
Adult
16.6.2.3.2.
Pediatric
16.6.2.4.
Argentina
Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-User
16.6.2.4.1.
Hospitals
and Clinics
16.6.2.4.2.
Research
and Academic Institutes
16.6.2.4.3.
Diagnostics
16.6.2.4.4.
Pharma
Companies
16.6.2.4.5.
Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Offerings
16.6.3.1.1.
Diagnostic
Assays
16.6.3.1.2.
 Others
16.6.3.2.
Rest of
Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
16.6.3.2.1.
Serum
Biomarkers
16.6.3.2.2.
Liver
Biopsy and liver enzyme testing
16.6.3.2.3.
Echography
16.6.3.2.4.
Histological
assessment of liver tissue
16.6.3.2.5.
Physical
Examination
16.6.3.2.6.
Blood
Tests
16.6.3.2.7.
Imaging
Tests
16.6.3.2.8.
Magnetic
resonance imaging (MRI)
16.6.3.2.8.1. Ultrasound
16.6.3.2.8.2. Others
16.6.3.2.9.
Others
16.6.3.3.
Rest of
Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By Patient Type
16.6.3.3.1.
Adult
16.6.3.3.2.
Pediatric
16.6.3.4.
Rest of
Latin America Non-Alcoholic Steatohepatitis Diagnostics Market Revenue (US$ Mn)
and Forecasts, By End-User
16.6.3.4.1.
Hospitals
and Clinics
16.6.3.4.2.
Research
and Academic Institutes
16.6.3.4.3.
Diagnostics
16.6.3.4.4.
Pharma
Companies
16.6.3.4.5.
Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Offerings
16.7.3. By Diagnosis
16.7.4. By Patient Type
16.7.5. By End-User
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Galmed
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2.
Genfit
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3.
Intercept
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Other Market Participants
19. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com


Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.
